Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2650-2655

  Lutsar, Irja ^a,b   Friedland, Ian R ^a   Wubbel, Loretta ^a   McCoig, Cynthia C ^a   Jafri, Hasan S ^a   Ng, Winston ^a   Ghaffar, Faryal ^a   McCracken Jr , George H ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; GATIFLOXACIN; TROVAFLOXACIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG HALF LIFE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STREPTOCOCCUS PNEUMONIAE;

EID: 0031691111     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2650     Document Type: Article

References (20)

1. Craig, W. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
2. Dacey, R. G., and M. A. Sande. 1974. Effect of prohenecid on cerebrospinal fluid concentration of penicillin and cephalosporin derivates. Antimicrob. Agents Chemother. 6:437-441.
3. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
4. Friedland, I. R., S. Shelton, M. Paris, K. Rinderknecht, K. Ehrett, K. Krischer, and G. H. McCracken. 1993. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr. Infect. Dis. J. 12:196-200.
5. Gabrielson, J., and D. Weiner. 1997. Parameter estimation, p. 31-57. In J. Gabrielson and D. Weiner (ed.), Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 2nd ed. Swedish Pharmaceutical Press, Stockholm, Sweden.
6. Hopkins, S., D. Williams, M. Dunne, L. Marinovich, M. Edeline, E. Utt, and A. I. Dutse. 1996. A randomized controlled trial of oral or IV trovafloxacin vs. ceftriaxone in the treatment of epidemic meningococcal meningitis, abstr. LB-21. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy.
7. Hosaka, M., S. Kinoshita, T. Toyama, M. Otsuki, and T. Nishino. 1995. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J. Antimicrob. Chemother. 36:293-301.
8. Hosaka, M., T. Yasue, H. Fukuda, H. Tomizawa, H. Aoyama, and K. Hirai. 1992. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 36:2108-2117.
9. Kim, Y. S., Q. Liu, L. Chow, and M. G. Täuber. 1997. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1186-1189.
10. Madras-Kelly, K. J., B. E. Ostergaard, L. B. Hovde, and J. C. Rotschafer. 1996. Twenty-four-hour area under the concentration-time curve/MIC ratios as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 40:627-632.
11. Nakashima, M., T. Uematsu, K. Kosuge, H. Kusajima, T. Ooie, Y. Masuda, R. Ishida, and H. Uchida. 1995. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39:2635-2640.
12. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 3rd ed. Approved standard. NCCLS publication no. M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. Nau, R., and H. W. Prange. 1996. Estimation of steady state antibiotic concentration in cerebrospinal fluid from single dose kinetics. Eur. J. Clin. Pharmacol. 49:407-409.
14. Nau, R., T. Schmidt, K. Kaye, J. L. Froula, and M. G. Täuber. 1995. Quinolone antibiotics in therapy of experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 39:593-597.
15. Ooie, T., H. Suzuki, T. Terasaki, and Y. Sugiyama. 1996. Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs. J. Pharmacol. Exp. Ther. 278:590-596.
16. Paris, M. M., O. Ramilo, and G. H. McCracken. 1995. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 39:2171-2175.
17. Scheld, W. M., and M. A. Sande. 1983. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J. Clin. Investig. 71:411-419.
18. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles. I. Relationship between AUC above MIC and area under the inhibitory curve of cefomenoxime, ciprofloxacin, and tobramycin. DICP-Ann. Pharmacother. 25:1050-1057.
19. Simon, H. J., and E. J. Yin. 1970. Microbioassay of antimicrobial agents. Appl. Microbiol. 19:573-579.
20. Wakabayashi, E., and S. Mitsuhashi. 1994. In vitro antibacterial activity of AM-1155 a novel 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 38:594-601.